First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer Meeting Abstract
| Authors: | Moore, K.; Bouberhan, S.; Hamilton, E.; Liu, J. Y.; O'Cearbhaill, R.; O'Malley, D.; Papadimitriou, K.; Schröder, D.; Van Nieuwenhuysen, E.; Yoo, S. Y.; Wang, B.; Peterman, M.; Gonçalves, P.; Schmidt, T.; Zhu, M.; Lowy, I.; Uldrick, T.; Miller, E. |
| Abstract Title: | First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer |
| Meeting Title: | IGCS 2023 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Nov 5-7 |
| Meeting Location: | Seoul, South Korea |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2023-11-01 |
| Start Page: | A254 |
| End Page: | A255 |
| Language: | English |
| ACCESSION: | WOS:001262421600174 |
| DOI: | 10.1136/ijgc-2023-IGCS.480 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TP020/#1513 -- Source: Wos |
